The pharmaceutical industry is under increased pressure to advance the development of new therapies in a fast and efficient manner, whilst ensuring the safety and quality of data.
The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.
The growing demands for sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in clinical trials require expert, dedicated research staff and facilities. However, typical clinical trial sites often lack dedicated personnel and expertise, forcing pharmaceutical companies to involve multiple sites to complete their trials. This results in high costs, delays, and quality issues for PROOF-OF-CONCEPT trials with relatively low patient numbers (12 to 200).
At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.
All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.
Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a budget reduction of at least 50% for Phase IB/IIA PROOF-OF-CONCEPT trials.
Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs
In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.
We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.
We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.
We are delighted to announce the opening of ARENSIA Research Clinic in the USA, located in Phoenix, Arizona! Our mission for the clinic in the US a...
READ MOREWe are delighted to share one of the most recent achievements at ARENSIA! Three ARENSIA clinics in Romania, Moldova, and Georgia have just completed t...
READ MOREARENSIA is delighted to introduce its latest face-to-face summit platform: INNOVATIONXCHANGE! On November 6th, we will inaugurate our first event a...
READ MORENeuroscience clinical trials thrive on a diverse range of factors such as novel target identification methods, comprehensive AI integration, real-worl...
READ MOREARENSIA Clinic in Tbilisi has expanded its facilities to 800 sqm and its staff to 50 FTEs, with more medics and more nurses - proof of our commitment ...
READ MOREFantastic event and vivid discussions at yesterday’s “Clinical Trials in Ukraine” conference. We are thankful to the host, The Minis...
READ MOREFollowing a successful day at Ukraine’s Recovery Conference in London, a delightful evening at the reception at Lancaster House! Our CEO, D...
READ MORE